Search Content

Search through available content in NewswireAPI.

Quick Menu features require JavaScript!

New Strong Sell Stocks for September 24th

WHD, CSL and CCS have been added to the Zacks Rank #5 (Strong Sell) List on September 24, 2025.

zacks.com — 38 minutes ago

BigBear.ai (BBAI) Moves 12.9% Higher: Will This Strength Last?

BigBear.ai (BBAI) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

zacks.com — 1 hour ago

The Zacks Analyst Blog Highlights Apple, Eli Lilly, Chevron and Monarch Cement

Apple, Eli Lilly, Chevron, and Monarch Cement show mixed performance, with growth in services, strong drug demand and strategic acquisitions.

zacks.com — 2 hours ago

Karyopharm Therapeutics (KPTI) Moves 27.9% Higher: Will This Strength Last?

Karyopharm Therapeutics (KPTI) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

zacks.com — 2 hours ago

The Zacks Analyst Blog Highlights Costco Wholesale, Ross Stores, Target and Dollar General

Costco gears up for Q4 earnings with strong sales momentum and loyal members, but premium valuation and mixed signals keep investors cautious.

zacks.com — 2 hours ago

AudioEye (AEYE) Declines More Than Market: Some Information for Investors

In the latest trading session, AudioEye (AEYE) closed at $13.93, marking a -1.62% move from the previous day.

zacks.com — 13 hours ago

The Trade Desk (TTD) Gains As Market Dips: What You Should Know

The Trade Desk (TTD) concluded the recent trading session at $46.86, signifying a +1.54% move from its prior day's close.

zacks.com — 13 hours ago

The Zacks Analyst Blog Highlights NVIDIA, CoreWeave, Nebius and Apple

NVIDIA's $100B OpenAI partnership and surging iPhone 17 demand push markets and tech giants to record highs.

zacks.com — 16 hours ago

IONS' Rare Neurological Disease Drug Meets Late-Stage Study Goal

Ionis' zilganersen hits its phase III goal in Alexander disease, paving the way for a potential FDA filing in early 2026.

zacks.com — 17 hours ago

Will Sysco's Expansion Efforts and Market Leadership Fuel Growth?

SYY expands through acquisitions, innovation and new formats, offsetting soft restaurant demand and inflationary headwinds.

zacks.com — 17 hours ago

OPFI vs. FUTU: Which Fintech Stock Is the Smarter Buy Right Now?

OppFi lifts guidance with AI-driven lending growth and strong credit quality, while Futu Holdings posts surging revenues and margins.

zacks.com — 17 hours ago

Continue

Please wait ...